For information on this past event please contact Meetings Management

Provisional Conference Program

Friday 27th April 2007

08.00-08.30
LATE BREAKER PRESENTATION
‘GAVI country experience with the introduction of rotavirus vaccine: The Merck-Nicaragua RotaTeq partnership’
Christopher Nelson (Merck Inc., USA)

SESSION 9:
SPECIAL SESSION:

‘Health Economics and their Impact on Enteric Vaccines’
Moderators: Duncan Steele (WHO, Geneva, Switzerland) and Umesh Parashar (CDC, Atlanta, USA)

08.30-08.50
‘Decision making for enteric disease control through vaccination: Prospects and challenges‘
Lara Wolfson (WHO, Geneva, Switzerland)

08.50-09.10
‘The challenges in estimating disease burden for understanding the potential impact of vaccination against enteric diseases’
Karen Kotloff (CVD, Maryland, USA)

09.10-09.30
‘Impact of delays in immunization timing and disparities in access on the impacted cost-effectiveness of rotavirus vaccination’
Rick Rheigans (Emory University, Atlanta, USA)

09.30-09.50
‘Challenges and opportunities in financing the enteric vaccines’
Damian Walker (Johns Hopkins University, Baltimore, USA)

09.50-10.15
Discussion Time

10.15-10.45
Coffee Break & Posters

10.45-11.15
‘The experience of the Rotavirus Vaccine Program in mobilizing resources for vaccines’
Deborah Atherly (PATH, Seattle, USA)

11.15-11.35
‘Innovative financing options for the introduction of enteric vaccines in Vietnam and Indonesia’
Luis Jodar (International Vaccine Institute, Seoul, South Korea)

11.35-11.55
‘School based Typhoid vaccination: A proposal for Pakistan’
Zulfi Bhutta (Aga Khan University, Pakistan)

11.55-12.10
‘Poverty focused assistance and mobilising funding for vaccination’
E.A.S. Nelson (The Chinese University of Hong Kong, China)

12.10-13.00
Panel Discussion:
‘Prospects and Challenges for New Enteric Vaccine Initiatives’
Discussion Leaders to be confirmed

13.00-14.00
Lunch & Posters

SESSION 10:
TRAVELLER VACCINES
Moderator: Eszter Nagy (Intercell AG, Vienna, Austria)

14.00-14.30
‘Towards protein based vaccines for the prevention of bacterial diarrhoea’
Eszter Nagy (Intercell AG, Vienna, Austria)

14.30-14.50
‘Development of a recombinant subunit vaccine for the prevention of diarrhoeal disease caused by Campylobacter jejuni in travellers’
Michael Darsley (ACE Biosciences A/S, Odense, Denmark)

14.50-15.10
‘Safety and immunogenicity of a recombinant Campylobacter flagellin vaccine in adult volunteers’
S. Baqar, J. Lapa, M. Nelson, C. Lin, C. Porter, C. Williams, T. Gilliland, R. Arora, J. Saunders, P. Guerry, J. Sanders
and D. Tribble (NMRC/WRAIR, Silver Spring, Maryland, USA)

15.10-15.30
‘Construction and preclinical evaluation of a V. cholerae peru-15 (CholeraGarde) strain that expresses high levels of CTB for use as a vaccine against entertoxigenic Escherchia coli (ETEC)’
Kenneth Roland, Cheryl Cloninger, Lawrence Thomas, Craig Rouskey and Kevin P. Killeen (AVANT Immunotherapeutics Inc., Needham, Masachusetts, USA)

15.30-15.50
‘Mechanisms of protection of a Lectin-based amebiasis vaccine’
Eric R. Houpt, Lisa Barroso, Suzanne Stroup, Lauren Lockhart, Amon Asgharpour, Joel Herbein, David Lyerly and William A. Petri, Jr. (University of Virginia, Charlottesville, USA)

15.50-16.05
Tea Break & Posters Breakdown

SESSION 11:
LATE BREAKING PRESENTATIONS
Moderator: To be confirmed

16.05-16.35
‘MyD88 signalling through TLR4 contributes to pathogen specific Bcell responses’
Margaret F. Connor, S.E. Blutt, S. Akira and L. Dastin (Baylor College of Medicine, Houston, Texas, USA)

16.35-16.55
‘Product development and clinical plan for a mucosally-delivered Norwalk vaccine’
Bryan Steadman, Michael Hinchcliffe, William T. Tino, Susan K. Wimer, Richard Sublett and Charles Richardson (LigoCyte Pharmaceuticals Inc., Bozeman, Montana, USA)

16.55-17.10
‘Recombinant rotavirus vaccine produced in milk of transgenic rabbits: protective efficacy in mouse after intrarectal delivery with cholera toxin or LT R192G’
Nathalie Parez et al. (Hopital Armand Trousseau, Paris, France)

17.10-17.30
‘Vaccination reduces shedding and colonization of E. coli 0157:H7 in cattle’
D.R. Rogan et al. (Bioniche Animal Health, Belleville, Ontario, Canada)

SESSION 12:
CLOSING PLENARY PRESENTATION
Moderator: Roger Glass (NIH, Washington DC, USA)

17.30-18.00
‘Future challenges for the clinical evaluation of vaccines against enteric infections’
John Clemens (IVI, Seoul, South Korea)

Summary & Closing Remarks by
Dr Roger Glass (NIH, Washington DC, USA)

This final programme is correct at the time of printing, however the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.